Telegraph Hill Partners
Telegraph Hill Partners (founded 2001) is a venture investor that provides growth capital and strategic guidance to private life science, medical device and healthcare companies. The firm positions itself to support portfolio growth and profitability through capital deployment and hands-on strategic support.
Telegraph Hill Partners
San Francisco, California, United States, North America
Services
Growth capital / equity investments
Provides growth-stage capital to private life science, medical device and healthcare companies.
Strategic guidance and operational support
Offers strategic guidance intended to help portfolio companies drive growth and improve profitability while maintaining organizational vision.
Follow-on and growth funding to support M&A and product development
Provides additional funding to portfolio companies for continued growth, technology and product development and to support strategic transactions.
Growth capital / equity investments
Provides growth-stage capital to private life science, medical device and healthcare companies.
Strategic guidance and operational support
Offers strategic guidance intended to help portfolio companies drive growth and improve profitability while maintaining organizational vision.
Follow-on and growth funding to support M&A and product development
Provides additional funding to portfolio companies for continued growth, technology and product development and to support strategic transactions.
Portfolio
Akoya acquired PerkinElmer's Quantitative Pathology Solutions portfolio; Telegraph Hill Partners provided additional funding to support Akoya's growth and product/technology development. Akoya is described in the source as "a Telegraph Hill Partners (THP) company."
#Multiparameter tissue imaging / quantitative pathology
Nimble is described as being backed by founding investors Telegraph Hill Partners and Roche Ventures; its lead asset was an investigational oral peptide IL23R inhibitor in preclinical development. The company was the subject of a proposed acquisition by AbbVie (Dec 13, 2024).
#Biotechnology — oral peptide therapeutics
Multiple press items on the THP site reference Agena products and regulatory milestones (EUA and CE-IVD marking) for SARS-CoV-2 panels, partnerships (e.g., Simcere, Assurex Health), and applications in high-throughput molecular testing.
#Genetic analysis systems / molecular diagnostics
Carterra published a development of a SARS-CoV-2 Spike Protein RBD SPR biosensor chip and a label-free assay to measure IgG, IgM, and IgA from small serum volumes running on its LSA HT-SPR platform.
#High-throughput antibody screening / biosensor platforms
Active Motif Shanghai used single-cell screening technology to isolate, sequence and express human antibodies from COVID-19 patients; THP site contains the press item describing this work.
#Epigenetics research tools / reagents
Akoya acquired PerkinElmer's Quantitative Pathology Solutions portfolio; Telegraph Hill Partners provided additional funding to support Akoya's growth and product/technology development. Akoya is described in the source as "a Telegraph Hill Partners (THP) company."
#Multiparameter tissue imaging / quantitative pathology
Nimble is described as being backed by founding investors Telegraph Hill Partners and Roche Ventures; its lead asset was an investigational oral peptide IL23R inhibitor in preclinical development. The company was the subject of a proposed acquisition by AbbVie (Dec 13, 2024).
#Biotechnology — oral peptide therapeutics
Multiple press items on the THP site reference Agena products and regulatory milestones (EUA and CE-IVD marking) for SARS-CoV-2 panels, partnerships (e.g., Simcere, Assurex Health), and applications in high-throughput molecular testing.
#Genetic analysis systems / molecular diagnostics
Carterra published a development of a SARS-CoV-2 Spike Protein RBD SPR biosensor chip and a label-free assay to measure IgG, IgM, and IgA from small serum volumes running on its LSA HT-SPR platform.
#High-throughput antibody screening / biosensor platforms
Active Motif Shanghai used single-cell screening technology to isolate, sequence and express human antibodies from COVID-19 patients; THP site contains the press item describing this work.
#Epigenetics research tools / reagents